Bal Pharma Limited (NSE: BALPHARMA | BSE: 524824)
Source: Bal Pharma Limited Annual Report FY 2025-26 (Fiscal Year Ended March 31, 2026) 📊 Stock Screeners
Bal Pharma Limited operates as an integrated, multi-specialty Indian pharmaceutical manufacturer catering to both domestic and international healthcare markets. The company’s core business engine is structured around two synchronized verticals: Active Pharmaceutical Ingredients (APIs) and finished dosage Formulations.
- Therapeutic Specializations: Anti-diabetic medicines (Gliclazide, Vildagliptin, Sitagliptin, Empagliflozin, Dapagliflozin) and anti-allergy actives (Ebastine, Bilastine).
- Raw Material Sourcing Profile: Indigenous raw material purchases accounted for ₹96.66 Crores (60.05% of total consumption), while imported raw materials totaled ₹64.31 Crores (39.95% of total consumption) in FY 2025-26.
- Schedule III Operating Ratios: Inventory turnover stood at 1.44x, trade receivables turnover at 3.35x, and net capital turnover stood at 23.96x.
- Customer Concentration: Sourcing and sales include ongoing commercial relationships with strategic pharma partners such as Micro Labs Limited (which generated ₹2.47 Crores in revenue in FY 2025-26) and export procurement through Desa Marketing International.
📋 Quick Facts / Company Snapshot: Bal Pharma Limited (NSE: BALPHARMA | BSE: 524824)
| Attribute | Disclosed Detail |
|---|---|
| Official Company Name | Bal Pharma Limited |
| Corporate Identity Number (CIN) | L85110KA1987PLC008368 |
| ISIN | INE083D01012 |
| Stock Exchange Listing | NSE Symbol: BALPHARMA | BSE Scrip Code: 524824 |
| Date of Incorporation / Founding Year | May 19, 1987 |
| Founders / Key Founding Figures | Mr. Shailesh Siroya (Chief Promoter & Managing Director) |
| Registered Office | 21-22, Bommasandra Industrial Area, Bommasandra Industrial Estate, Bangalore, Bangalore South, Karnataka – 560099, India |
| Corporate Headquarters | 5th Floor, Lakshmi Narayan Complex, 10/1 Palace Road, Bengaluru, Chickpet, Bangalore South, Karnataka – 560053, India |
| Telephone & Investor Relations Email | Tel: +91 080 – 41379500 | Email: investors@balpharma.com / secretarial@balpharma.com |
| Chairman & Managing Director | Mr. Shailesh Siroya |
| Chief Financial Officer (CFO) | Mr. Bharath Bhushan D. V. |
| Company Secretary & Compliance Officer | Mr. Shreepada M. L. (w.e.f. June 23, 2026) / Mr. Abdul Basith (relieved May 11, 2026) |
| Promoter & Holding Group | Shailesh Siroya and Promoter Group (including Micro Labs Limited, Anita Siroya) |
| Industry / Sector Classification | Pharmaceuticals & Life Sciences (Active Pharmaceutical Ingredients & Formulations) |
| Total Permanent Workforce | 939 permanent employees (including 91 permanent women employees as on March 31, 2026) |
| Manufacturing Plants Count | 6 manufacturing units (Bangalore, Rudrapur, Sangli, Udaipur, and Kenjal-Pune) |
| Credit Ratings & Rating Agency | Acuité Ratings & Research: Bank Limits / Term Loan: BBB- / Stable; Non-Fund Based Limits: A3 |
| Statutory Auditor | Messrs. SSJNB & Co., Chartered Accountants, Bangalore (FRN: 013976S) |
| Secretarial Auditor | Mr. Parameshwar G. Bhat, Practising Company Secretary, Bangalore (CP No.: 11004) |
| Cost Auditor | Messrs. GNV & Associates, Cost Accountants, Bangalore (FRN: 000150) |
| Internal Auditor | Messrs. Murugesh & Company, Chartered Accountants, Bangalore (FRN: 002233S) |
| Registrar and Share Transfer Agent (RTA) | MUFG Intime India Private Limited (formerly Link Intime India Pvt. Ltd.), Mumbai |
🏢 The Corporate Identity: Bal Pharma Overview, Promoters & History
The Big Picture: Business Model & Core Value Proposition
Bal Pharma Limited operates as an integrated, multi-specialty Indian pharmaceutical manufacturer catering to both domestic and international healthcare markets. The company’s core business engine is structured around two synchronized verticals: Active Pharmaceutical Ingredients (APIs) and finished dosage Formulations. With regulatory accreditations spanning across five continents, the company exports prescription pharmaceuticals, specialty therapeutic drugs, and bulk generic actives to over 30 countries globally.
The enterprise focuses on delivering affordable, high-quality branded generics and active ingredients across key therapeutic domains, including endocrinology (anti-diabetic medicines), allergy and respiratory care (anti-histamines), cardiology, and central nervous system treatments. By maintaining integrated research, product development, synthesis, and manufacturing units, Bal Pharma captures value across the pharmaceutical life cycle from intermediate chemical synthesis to finished clinical dosage forms.
The Founders, Promoters & Their Legacy
The enterprise was founded and spearheaded by Mr. Shailesh Siroya, who has served as the Chairman and Managing Director since August 1, 1994. Holding a Post Graduate Degree in Management Sciences from the University of Akron, Ohio, USA, Mr. Siroya brings over three decades of executive leadership and commercial insight to the group. Under his stewardship, Bal Pharma transformed from a local formulation facility into an export-oriented, cGMP-compliant manufacturer with extensive international distribution networks.
The promoter group is supported by key strategic stakeholders, notably Micro Labs Limited, a major Indian pharmaceutical conglomerate holding a significant 12.64% equity interest in the entity. The promoter family equity holding, which includes Anita Siroya, Dilip Surana, Anand Surana, and related family members, provides strategic stability and operational depth to the company’s long-term corporate governance framework.
The Journey: Corporate History & Key Milestones
Incorporated on May 19, 1987, Bal Pharma embarked on its manufacturing journey with the commissioning of its initial finished formulation facility in Bangalore in 1992. Over the subsequent three decades, the company steadily executed backward integration and geographic expansion:
- 1987–1992: Incorporation as a public limited enterprise and subsequent commissioning of Unit 1 (Formulations) in Bommasandra, Bangalore.
- 1996: Commissioning of Unit 2 in Bangalore as a dedicated, multipurpose API manufacturing plant to support captive formulation requirements and commercial export operations.
- Geographic Expansion: Setting up Unit 4 at IIE-Pantnagar, Rudrapur (Uttarakhand) in an excise-free zone to scale up regulated-market oral solid dosage production.
- API & Intermediates Scaling: Establishment of Unit 5 at Sangli, Maharashtra for intermediate chemical processing, and subsequent addition of Unit 6 in Udaipur, Rajasthan.
- FY 2024–25 Amalgamation: Strategic corporate consolidation through the amalgamation of wholly owned subsidiary Golden Drugs Private Limited into Bal Pharma Limited pursuant to the Hon’ble NCLT order dated March 26, 2025, taking effect in April 2025.
- FY 2025–26 Modernization: Substantial completion of Schedule M upgrades across domestic manufacturing plants and the renewal of European GMP accreditations for Unit 2 and Unit 4.
The Corporate Umbrella & Group Structure
Bal Pharma Limited acts as the operational corporate parent overseeing several operating subsidiaries and specialized platforms:
- Lifezen Healthcare Private Limited (99.40% subsidiary): Focuses on the over-the-counter (OTC) consumer wellness and specialized consumer healthcare segments.
- Bal Research Foundation (80.00% subsidiary): Functions as a dedicated institutional R&D center focused on advanced drug delivery systems and novel synthesis routes.
- Balance Clinics LLP (80.00% partner entity): A specialized clinical healthcare venture structured for diabetic wellness, lifestyle management, and outpatient clinical care.
- Aurum Research & Analytical Solutions Private Limited (95.00% subsidiary): Dedicated to commercial contract research, testing, and analytical pharmaceutical solutions.
⚙️ The Business Engine: Bal Pharma Segments, Brands, Products & Operations
The Core Divisions & Segment Revenue Breakdown
Bal Pharma reports its financial results under a single unified segment pursuant to Ind AS 108: “Manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients”. However, internally the company evaluates its performance along two core functional product divisions: APIs & Intermediates and Finished Dosage Formulations.
| Business Segment / Division | Revenue Contribution (%) | Operational Focus & Core Product Lines |
|---|---|---|
| Active Pharmaceutical Ingredients (API) | 50% | Bulk active synthesis, regulatory filings (CEP/DMF), anti-diabetic and anti-histamine APIs |
| Finished Formulations | 50% | Oral solids (tablets, capsules), liquids, ointments, branded generics, and contract manufacturing |
| Total Operations | 100% | Balanced revenue split between bulk APIs and finished dosages |
The Product & Service Catalog (with Operational KPIs, Order Book & Customer Concentration)
The company maintains a broad catalog spanning life-saving prescription medicines, bulk actives, and hospital care products. Bal Pharma’s commercial strength is anchored in therapeutic categories such as anti-diabetics, anti-histamines, cardiovascular treatments, and anti-inflammatory formulations.
The API pipeline is led by market-leading bulk actives where the company holds Certificates of Suitability (CEP) and regulatory filings with global authorities. In the formulations vertical, the company manufactures generic oral tablets, enteric-coated formulations, and topical creams.
- Therapeutic Specializations: Anti-diabetic medicines (Gliclazide, Vildagliptin, Sitagliptin, Empagliflozin, Dapagliflozin) and anti-allergy actives (Ebastine, Bilastine).
- Raw Material Sourcing Profile: Indigenous raw material purchases accounted for ₹96.66 Crores (60.05% of total consumption), while imported raw materials totaled ₹64.31 Crores (39.95% of total consumption) in FY 2025-26.
- Schedule III Operating Ratios: Inventory turnover stood at 1.44x, trade receivables turnover at 3.35x, and net capital turnover stood at 23.96x.
- Customer Concentration: Sourcing and sales include ongoing commercial relationships with strategic pharma partners such as Micro Labs Limited (which generated ₹2.47 Crores in revenue in FY 2025-26) and export procurement through Desa Marketing International.
The Names You Know: Key Brands & Flagship Portfolio
| Brand / Product Name | Category / Business Segment | Target Market & Key Positioning |
|---|---|---|
| Gliclazide Bulk API | Active Pharmaceutical Ingredient | Regulated global markets; second-generation sulfonylurea for Type 2 diabetes management |
| Ebastine Bulk API | Active Pharmaceutical Ingredient | International markets (CEP approved); non-sedating second-generation H1 anti-histamine |
| Dapagliflozin Propanediol | API Pipeline (Under Commercialization) | SGLT2 inhibitor for glycemic control and renal protection in diabetic patients |
| Empagliflozin | API Pipeline (Under Commercialization) | Selective SGLT2 inhibitor therapeutic category for cardiovascular and diabetes therapies |
| Bilastine | API Pipeline (Under Commercialization) | Novel second-generation anti-histamine for allergic rhinitis and urticaria management |
| Dabigatran Etexilate Mesylate | API Pipeline (Commercialization Underway) | Novel oral direct thrombin inhibitor anticoagulant to treat and prevent stroke and thromboembolism |
| Baclofen | API Pipeline (Commercialization Underway) | Central nervous system antispasmodic and skeletal muscle relaxant |
| Hydrochlorothiazide | API Pipeline (Stability Testing Phase) | Thiazide diuretic for chronic hypertension, cardiac edema, and fluid overload management |
Mapping the Domestic & Global Reach (India vs. Exports)
Bal Pharma maintains an export-heavy revenue mix, deriving almost two-thirds of its top-line from international distributors, overseas multinational pharmaceutical companies, and contract formulation buyers.
| Geographic Market | Revenue Contribution (%) | Operational Reach & Regulatory Approvals |
|---|---|---|
| Export Markets (International) | 63% | Over 30 countries across Europe, Australia, Middle East, Africa, South East Asia, Latin America |
| Domestic Markets (India) | 37% | Pan-India distribution across hospitals, institutional tenders, wholesale distributors, retail OTC |
| Total Geographic Mix | 100% | Total foreign exchange earnings of ₹172.67 Crores generated in FY 2025-26 |
The Brick & Mortar Footprint: Manufacturing Plants, R&D & Offices
The manufacturing infrastructure of Bal Pharma comprises specialized processing facilities located across Karnataka, Uttarakhand, Maharashtra, and Rajasthan:
- Unit 1 (Bommasandra Industrial Area, Bangalore, Karnataka): Commissioned in 1992; dedicated to oral solid and liquid formulations; certified by WHO-GMP, ISO 9001:2008, ISO 14001:2015, and ISO 45001:2018. Serves African, Middle Eastern, and Latin American export markets and contract manufacturing.
- Unit 2 (Bommasandra Industrial Area, Bangalore, Karnataka): Commissioned in 1996; multi-purpose API synthesis facility accredited by WHO-GMP, EDQM (Europe), TGA (Australia), PMDA (Japan), Health Canada, KFDA (Korea), and COFEPRIS (Mexico). Features an in-house DSIR-recognized R&D laboratory.
- Unit 3 (Kenjal, Dist. Bhor, Maharashtra): Parenterals and IV fluids facility; currently non-operational/suspended due to high input costs and non-core restructuring.
- Unit 4 (IIE-Pantnagar, Rudrapur, Uttarakhand): High-capacity formulation plant located in an excise-free zone producing tablets, capsules, and ointments. Holds EU-GMP (Malta Medicines Authority) approval alongside accreditations from Zimbabwe (MCAZ), Kenya (PPB), Uganda (NDA), Ethiopia (FMHACA), and Nigeria (NAFDAC).
- Unit 5 (Sangli, Maharashtra): Specialized multi-purpose chemical intermediate facility operating under WHO-GMP norms; provides critical captive intermediates feeding into Unit 2 API manufacturing.
- Unit 6 (Mewar Industrial Area, Madri, Udaipur, Rajasthan): Large-scale API facility (formerly Golden Drugs Pvt. Ltd.); holds CEP approvals for Gliclazide and Ebastine; supplies European, Latin American, and Asian export channels.
📊 The Financial Health: Bal Pharma Financial Statements & Numbers Simplified
Multi-Year Financial Highlights (₹ in Crores)
A ten-year longitudinal review of Bal Pharma’s financial metrics reveals consistent growth in operational revenues, transitioning from ₹232.01 Crores in FY 2016-17 to ₹312.80 Crores in FY 2025-26 on a standalone basis, alongside steadily expanding tangible fixed assets.
| Metric (Standalone Basis) | FY 25-26 | FY 24-25 | FY 23-24 | FY 22-23 | FY 21-22 | FY 20-21 | FY 19-20 | FY 18-19 | FY 17-18 | FY 16-17 | Latest YoY (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover / Total Income | 312.80 | 304.65 | 341.89 | 305.25 | 286.86 | 252.00 | 174.30 | 225.83 | 211.52 | 232.01 | +2.68% |
| Profit / (Loss) Before Tax | 6.37 | 5.73 | 12.11 | 8.55 | 12.06 | 9.80 | (9.08) | 4.41 | 8.45 | 8.07 | +11.17% |
| Taxes & Provisions | (0.39) | (2.07) | 1.83 | 2.42 | 3.48 | 0.70 | (0.17) | (2.35) | 2.52 | 3.10 | -81.16% |
| Profit / (Loss) After Tax | 6.75 | 7.80 | 10.27 | 6.13 | 8.58 | 9.10 | (9.21) | 6.76 | 5.94 | 4.97 | -13.46% |
| Net Tangible Fixed Assets | 76.73 | 70.95 | 53.18 | 52.62 | 44.92 | 45.42 | 49.74 | 51.27 | 53.82 | 56.89 | +8.15% |
| Net Intangible Assets | 13.42 | 12.00 | 11.38 | 10.45 | 0.98 | 7.23 | 6.39 | 5.67 | 4.47 | 4.66 | +11.83% |
| Net Current Assets | 32.33 | 34.19 | 71.98 | 57.79 | 55.96 | 46.33 | 32.52 | 44.32 | 48.15 | 27.48 | -5.44% |
| Equity Share Capital | 15.92 | 15.92 | 15.80 | 15.69 | 14.82 | 14.82 | 14.17 | 14.17 | 14.17 | 14.17 | 0.00% |
| Reserves & Surplus | 88.18 | 82.90 | 89.78 | 80.34 | 72.50 | 64.50 | 51.77 | 62.69 | 58.06 | 61.27 | +6.37% |
| Basic Earnings Per Share (₹) | 4.51 | 4.89 | 6.72 | 3.90 | 5.79 | 6.41 | (6.28) | 4.77 | 4.19 | 3.51 | -7.77% |
| Dividend Payout (%) | 12% | 12% | 12% | 10% | 10% | 10% | – | 10% | 10% | 10% | – |
| Book Value Per Equity Share (₹) | 65.00 | 62.00 | 67.00 | 61.00 | 59.00 | 54.00 | 47.00 | 54.00 | 51.00 | 47.75 | +4.84% |
Earnings, Expenses, & Take-Home Profits (Consolidated Profit & Loss)
The consolidated performance for FY 2025-26 demonstrated steady operational expansion, with Consolidated Revenue from Operations climbing 2.83% to ₹311.66 Crores compared to ₹303.08 Crores in FY 2024-25. Total Income reached ₹313.59 Crores. Operating expenditures were influenced by ongoing raw material consumption and elevated Schedule M compliance maintenance costs, leading to a Profit Before Tax of ₹5.93 Crores.
| Statement of Profit and Loss Line Item (₹ in Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Revenue from Operations | 311.66 | 303.08 | +2.83% |
| Other Income | 1.93 | 2.20 | -12.27% |
| Total Income | 313.59 | 305.29 | +2.72% |
| Expenses | |||
| Cost of Materials Consumed | 160.97 | 149.89 | +7.39% |
| Purchase of Traded Goods | 9.23 | 15.06 | -38.71% |
| (Increase) / Decrease in Inventories of Finished Goods & WIP | (12.23) | (7.05) | +73.48% |
| Employee Benefits Expense | 66.46 | 62.40 | +6.51% |
| Finance Costs | 16.82 | 16.85 | -0.18% |
| Depreciation and Amortisation Expense | 11.08 | 9.77 | +13.41% |
| Other Expenses | 55.33 | 53.23 | +3.95% |
| Total Expenses | 307.66 | 300.15 | +2.50% |
| Profit Before Exceptional Items and Tax | 5.93 | 5.14 | +15.37% |
| Profit Before Tax (PBT) | 5.93 | 5.14 | +15.37% |
| Tax Expense: Current Tax | 0.00 | 0.00 | N/M |
| Tax Expense: Excess / Short Provision of Tax Written Back | 0.00 | (0.14) | -100.00% |
| Tax Expense: Deferred Tax Charge / (Credit) | (0.39) | (1.96) | -80.10% |
| Total Tax Expense / (Credit) | (0.39) | (2.10) | -81.43% |
| Profit / (Loss) for the Year (PAT) | 6.32 | 7.24 | -12.71% |
| Attributable to: Equity Holders of the Parent | 6.28 | 7.22 | -13.02% |
| Attributable to: Non-Controlling Interest | 0.04 | 0.02 | +100.00% |
| Other Comprehensive Income (Remeasurements of Post-Employment Benefits) | 0.44 | (0.03) | N/M |
| Total Comprehensive Income for the Year | 6.76 | 7.20 | -6.11% |
| Basic Earnings Per Share (₹) | 3.95 | 4.56 | -13.38% |
| Diluted Earnings Per Share (₹) | 3.95 | 4.56 | -13.38% |
Assets, Borrowings, & Net Worth (Consolidated Balance Sheet)
The consolidated balance sheet of Bal Pharma expanded to ₹375.54 Crores as of March 31, 2026, reflecting continuous capitalization of plant infrastructure, regulatory upgrades, and working capital investments. Total equity reached ₹82.25 Crores, backed by equity share capital of ₹15.92 Crores and other equity of ₹66.31 Crores.
| Consolidated Balance Sheet Line Item (₹ in Crores) | As at March 31, 2026 | As at March 31, 2025 | Latest YoY (%) |
|---|---|---|---|
| ASSETS | |||
| Non-Current Assets | |||
| Property, Plant and Equipment | 76.75 | 70.99 | +8.11% |
| Capital Work-in-Progress (CWIP) | 7.42 | 2.79 | +165.95% |
| Goodwill | 3.83 | 3.83 | 0.00% |
| Other Intangible Assets | 13.42 | 12.00 | +11.83% |
| Non-Current Financial Assets: Other Financial Assets | 8.07 | 7.13 | +13.18% |
| Deferred Tax Assets (Net) | 0.80 | 0.41 | +95.12% |
| Other Non-Current Assets | 3.01 | 3.68 | -18.21% |
| Total Non-Current Assets | 113.31 | 100.82 | +12.39% |
| Current Assets | |||
| Inventories | 116.36 | 103.02 | +12.95% |
| Current Financial Assets: Investments | 2.08 | 2.47 | -15.79% |
| Current Financial Assets: Trade Receivables | 93.63 | 92.44 | +1.29% |
| Current Financial Assets: Loans | 1.17 | 1.13 | +3.54% |
| Current Financial Assets: Cash and Cash Equivalents | 2.30 | 1.75 | +31.43% |
| Current Financial Assets: Other Bank Balances | 4.91 | 6.30 | -22.06% |
| Current Financial Assets: Other Financial Assets | 1.64 | 1.28 | +28.12% |
| Current Tax Assets (Net) | 0.13 | 0.99 | -86.87% |
| Other Current Assets | 40.01 | 25.49 | +56.96% |
| Total Current Assets | 262.23 | 234.87 | +11.65% |
| TOTAL ASSETS | 375.54 | 335.69 | +11.87% |
| EQUITY AND LIABILITIES | |||
| Equity | |||
| Equity Share Capital | 15.92 | 15.92 | 0.00% |
| Other Equity | 66.31 | 61.50 | +7.82% |
| Non-Controlling Interest | 0.03 | (0.01) | N/M |
| Total Equity | 82.25 | 77.40 | +6.27% |
| Non-Current Liabilities | |||
| Financial Liabilities: Borrowings (Term Loans & GECL) | 31.88 | 31.40 | +1.53% |
| Financial Liabilities: Other Financial Liabilities (Leases & Deposits) | 5.97 | 1.74 | +243.10% |
| Provisions (Non-Current) | 6.20 | 5.64 | +9.93% |
| Total Non-Current Liabilities | 44.06 | 38.79 | +13.59% |
| Current Liabilities | |||
| Financial Liabilities: Borrowings (Working Capital & Current Maturities) | 127.63 | 118.98 | +7.27% |
| Financial Liabilities: Trade Payables – MSME | 0.39 | 4.62 | -91.56% |
| Financial Liabilities: Trade Payables – Other than MSME | 88.58 | 77.07 | +14.93% |
| Financial Liabilities: Other Financial Liabilities | 24.62 | 10.74 | +129.24% |
| Other Current Liabilities | 7.23 | 6.93 | +4.33% |
| Provisions (Current) | 0.78 | 1.17 | -33.33% |
| Total Current Liabilities | 249.23 | 219.50 | +13.54% |
| Total Liabilities | 293.29 | 258.29 | +13.55% |
| TOTAL EQUITY AND LIABILITIES | 375.54 | 335.69 | +11.87% |
Working Capital Cycle & Schedule III Statutory Ratio Explanations
Working capital management remained a critical operational focus throughout FY 2025-26 as Bal Pharma navigated extended international freight schedules, supply-chain lead times for key starting materials, and plant modernization downtime.
| Statutory Ratio (Schedule III) | FY 2025-26 | FY 2024-25 | YoY Variance (%) | Management Explanation / Operational Driver |
|---|---|---|---|---|
| Current Ratio | 1.05 | 1.07 | -1.67% | Maintained stable liquidity coverage across short-term obligations |
| Debt-Equity Ratio | 1.94 | 1.94 | -0.18% | Total borrowings aligned with ongoing capital structure and capex plans |
| Debt Service Coverage Ratio (DSCR) | 1.58 | 1.58 | 0.00% | Operating earnings adequately met debt servicing and lease charges |
| Return on Equity (ROE) | 7.92% | 9.69% | -18.29% | Impacted by lower net profit due to temporary Schedule M capex disruptions |
| Inventory Turnover Ratio | 1.44 | 1.65 | -12.97% | Higher inventory of raw materials and WIP held during plant upgrades |
| Trade Receivables Turnover Ratio | 3.35 | 3.16 | +6.14% | Improved collections and receivables velocity in overseas accounts |
| Trade Payables Turnover Ratio | 2.06 | 2.18 | -5.15% | Slight extension of vendor payment cycles matching working capital lead times |
| Net Capital Turnover Ratio | 23.96 | 19.72 | +21.54% | Due to an increase in net working capital deployment towards year-end |
| Net Profit Ratio (%) | 6.32 | 2.39% | -15.07% | Elevated operating expenses and pricing pressures across selected generic APIs |
| Return on Capital Employed (ROCE) | 19.93% | 20.21% | -1.38% | Consistent operational returns on capital employed despite heavy capex |
Cash Flow: Tracking the Money Movement
Bal Pharma achieved a significant strengthening in its cash generation capabilities during FY 2025-26. Net Cash Generated from Operating Activities jumped 51.79% to ₹30.84 Crores compared to ₹20.32 Crores in FY 2024-25, driven by improved operating cash flows before working capital adjustments of ₹32.47 Crores.
| Consolidated Cash Flow Statement Component (₹ in Crores) | FY 2025-26 | FY 2024-25 | Latest YoY (%) |
|---|---|---|---|
| Profit / (Loss) Before Tax | 5.93 | 5.14 | +15.37% |
| Adjustments for Non-Cash & Non-Operating Items (Finance Costs, Depr., etc.) | 26.54 | 24.74 | +7.28% |
| Operating Cash Flow Before Working Capital Changes | 32.47 | 29.88 | +8.67% |
| Changes in Working Capital (Inventories, Receivables, Payables, Assets) | (1.64) | (7.49) | -78.10% |
| Cash Generated from Operations | 30.84 | 22.39 | +37.74% |
| Income Taxes (Paid) / Refund | 0.00 | (2.08) | -100.00% |
| Net Cash Generated from / (Used in) Operating Activities | 30.84 | 20.32 | +51.77% |
| Purchase of Property, Plant & Equipment (CapEx / CWIP / Intangibles) | 18.55 | 16.79 | +10.48% |
| Right to Use of Asset as per Ind AS 116 | (3.83) | (2.00) | +91.50% |
| Proceeds from Sale of Fixed Assets | 0.06 | 0.00 | N/M |
| Change in Fixed Deposits / Liquid Funds & Subsidiary ICDs | 0.78 | 3.13 | -75.08% |
| Interest Received | 0.84 | 0.74 | +13.51% |
| Net Cash Generated from / (Used in) Investing Activities | (20.70) | (14.92) | +38.74% |
| Proceeds from / (Repayment of) Long-Term Borrowings | 3.41 | (0.77) | N/M |
| Proceeds from / (Repayment of) Short-Term Borrowings | 5.72 | 11.55 | -50.48% |
| Dividend Paid on Equity Shares (Including Unpaid Dividends) | (1.91) | (1.91) | 0.00% |
| Money Received on Issue of Equity Shares / Options | (0.00) | 0.81 | -100.00% |
| Share Based Payment Reserve Adjustment | 0.00 | (0.67) | -100.00% |
| Interest Paid (Gross) | (16.81) | (16.85) | -0.24% |
| Net Cash Arising / (Used in) from Financing Activities | (9.59) | (7.84) | +22.32% |
| Net Increase / (Decrease) in Cash and Cash Equivalents | 0.55 | (2.44) | N/M |
| Cash and Cash Equivalents at Beginning of Year | 1.75 | 4.20 | -58.33% |
| Cash and Cash Equivalents at End of Year | 2.30 | 1.75 | +31.43% |
Funding the Future: CapEx, CWIP, R&D Intensity & Net Foreign Exchange
The company continued substantial capital allocation towards infrastructure upgrades and process R&D during the year. Total capital expenditure covering property, plant, equipment, and development projects amounted to ₹18.55 Crores, while capital work-in-progress stood at ₹7.42 Crores as of March 31, 2026.
Revenue expenditure incurred on Research and Development reached ₹4.26 Crores in FY 2025-26, representing 1.38% of total turnover, fully capitalized under intangible development assets in line with Ind AS 38. In terms of foreign currency dynamics, Bal Pharma was a substantial net foreign exchange earner, generating ₹172.67 Crores in export earnings against an outgo of ₹68.02 Crores (comprising raw material imports of ₹64.31 Crores and other foreign currency expenditures of ₹3.71 Crores).
👥 Power & Control: Bal Pharma Governance, Leadership & Shareholding Pattern
The Brain Trust: Board of Directors & Key Managerial Personnel (KMP)
As of March 31, 2026, the Board of Directors of Bal Pharma Limited comprised six directors, balancing executive oversight with three independent professionals, including an independent woman director.
| Name of Director / KMP | Designation / Role | DIN | Category |
|---|---|---|---|
| Mr. Shailesh Siroya | Chairman & Managing Director | 00048109 | Executive Director (Promoter) |
| Mr. Virupakshaya Himesh | Whole-Time Director (Chemical Engineer) | 08554422 | Executive Director (Retires by Rotation) |
| Mr. Ravindra Kumar Kothari | Non-Executive Director | 03418320 | Non-Executive, Non-Independent Director |
| Ms. Nicola Neeladri | Independent Director | 01997936 | Non-Executive, Independent Woman Director |
| Mr. Jatish Sheth | Independent Director (Audit Committee Chair) | 00581963 | Non-Executive, Independent Director |
| Dr. Mukesh Bheekamchand | Independent Director (Medical Professional) | 11295580 | Non-Executive, Independent Director |
| Mr. Bharath Bhushan D. V. | Chief Financial Officer (CFO) | – | Key Managerial Personnel |
| Mr. Shreepada M. L. | Company Secretary & Compliance Officer | – | Key Managerial Personnel (w.e.f. June 23, 2026) |
Who Owns the Stock? Shareholding Pattern
The issued, subscribed, and paid-up equity share capital of the company stands at ₹15.92 Crores, comprising 1,59,20,872 equity shares of face value ₹10 each. The promoters and promoter group hold a controlling 50.86% equity stake.
| Shareholder Category | Number of Shares Held | % of Total Issued Capital |
|---|---|---|
| Promoter & Promoter Group | 80,97,182 | 50.86% |
| Individual Promoters & HUF (Shailesh Siroya, Anita Siroya, etc.) | 60,85,446 | 38.22% |
| Corporate Bodies (Micro Labs Limited) | 20,11,736 | 12.64% |
| Institutional Investors | 21,566 | 0.14% |
| Foreign Portfolio Investors (FPI Corporate & Individual) | 21,566 | 0.14% |
| Public & Non-Institutional Shareholders | 78,02,124 | 49.00% |
| General Public (Individual Shareholders) | 52,22,341 | 32.80% |
| Non-Resident Indians (Repatriable & Non-Repatriable) | 19,29,329 | 12.12% |
| Hindu Undivided Families (HUF) | 4,15,423 | 2.61% |
| Investor Education and Protection Fund (IEPF) | 1,42,819 | 0.90% |
| Other Bodies Corporate, Clearing Members & Escrow | 92,212 | 0.58% |
| Total Issued Equity Shares | 1,59,20,872 | 100.00% |
🗺️ The Corporate Family Tree: Group Structure, Ratings & Contingent Liabilities
Subsidiaries, Associates, & Joint Ventures (Form AOC-1)
Bal Pharma consolidates four operating subsidiaries in its audited financial statements, covering consumer healthcare, medical research, clinical wellness, and laboratory testing.
| Entity Name | Relationship | Country | % Stake | Turnover (₹ Cr) | Profit / (Loss) After Tax (₹ Cr) |
|---|---|---|---|---|---|
| Lifezen Healthcare Private Limited | Subsidiary | India | 99.40% | 0.97 | (0.28) |
| Bal Research Foundation | Subsidiary | India | 80.00% | 0.00 | (0.04) |
| Balance Clinics LLP | Subsidiary / LLP | India | 80.00% | 0.61 | (0.10) |
| Aurum Research & Analytical Solutions Pvt. Ltd. | Subsidiary | India | 95.00% | 0.00 | (0.01) |
Strategic Investments, Credit Ratings, Banking Consortium & Contingent Liabilities
The company maintains structured banking arrangements across a consortium of scheduled commercial banks, including HDFC Bank, South Indian Bank, Canara Bank, Union Bank of India, Federal Bank, and SIDBI. Total non-current and current borrowings across credit lines, working capital facilities, and term loans stood at ₹159.52 Crores as of March 31, 2026.
Acuité Ratings & Research reaffirmed the company’s bank credit ratings at BBB- / Stable for long-term fund-based facilities and term loans, and A3 for short-term non-fund-based facilities.
- Income Tax Matters: ₹2.98 Crores pending across disputed corporate assessments.
- Excise, Customs & Service Tax: ₹2.23 Crores subject to show-cause notices and appellate proceedings.
- Goods and Services Tax (GST): ₹0.36 Crores under assessment (down from ₹11.60 Crores in the prior fiscal period).
- Capital Commitments: Nil capital commitments remaining to be executed on capital account as of year-end.
🎯 The Strategic Outlook: Competitive Moats, Risks, Growth Plans & FAQs
Competitive Advantages & Economic Moats
Bal Pharma’s operational model is anchored in multiple structural and regulatory barriers that protect its market position in specialized niche pharmaceuticals:
- Stringent Regulatory Approvals: Possession of European CEPs, EU-GMP (Malta), TGA Australia, PMDA Japan, and WHO-GMP accreditations enables high-margin API and formulation supply into regulated overseas markets.
- Deep Therapeutic Niche in Anti-Diabetics: Recognized as a leading global manufacturer of Gliclazide bulk active, supported by an advanced pipeline of next-generation oral anti-diabetics (Vildagliptin, Sitagliptin, Empagliflozin, Dapagliflozin).
- Backward Integrated Manufacturing: The Sangli intermediate facility supplies captive chemical blocks directly to the Bangalore API plant, insulating downstream formulations from external chemical price volatility.
- Established Global Footprint: Diversified commercial distribution across more than 30 emerging and regulated markets dampens single-country geopolitical disruptions.
What Could Go Wrong? Key Challenges & Business Risks
Despite steady operational progress, the enterprise is exposed to distinct industry and commercial risks:
- Chinese API Price Competition: Ongoing global pricing pressure in standard generic APIs resulting from excessive bulk chemical capacity in China poses a margin risk to active ingredient exports.
- High Financial Leverage: Total borrowings of ₹159.52 Crores result in annual finance charges of ₹16.82 Crores, absorbing a substantial portion of operating cash flows.
- Foreign Exchange Exposure: With 63% of revenues derived from exports and raw material imports of ₹64.31 Crores, operating margins remain vulnerable to unhedged currency swings.
- Regulatory Scrutiny: Strict domestic enforcement under revised Schedule M and regular international audits require continuous capital outlays for compliance.
The Next Chapter: Growth, Order Pipeline & CapEx Initiatives
Entering FY 2026-27, Bal Pharma has substantially concluded its primary Schedule M facility modernization and infrastructure overhauls across its manufacturing network. The Board has also approved the preferential issuance of 10,00,000 fully convertible equity warrants to promoter Mr. Shailesh Siroya to inject growth capital.
Growth will be driven by commercializing completed R&D formulations (Dabigatran, Bilastine, Baclofen, and SGLT2 inhibitors), re-energizing the OTC business under Lifezen Healthcare via digital and e-commerce distribution, and commissioning expanded capacities at the Unit 6 Udaipur API plant to service European and Latin American contracts.
The Verdict: Strategic Outlook & Conclusion
Bal Pharma Limited concludes FY 2025-26 with reinforced manufacturing infrastructure, renewed European accreditations, and healthy operating cash generation of ₹30.84 Crores. While operating margins reflect near-term pricing headwinds in bulk generic APIs and the financial cost of infrastructure upgrades, the completion of Schedule M projects positions the enterprise for operating leverage, improved capacity utilization, and steady cash flows across regulated export channels.
Frequently Asked Questions (FAQs) About Bal Pharma
Q1: What does Bal Pharma manufacture and what are its flagship products?
Bal Pharma Limited manufactures Active Pharmaceutical Ingredients (APIs), chemical intermediates, and finished oral dosage formulations. Its primary therapeutic specializations are anti-diabetic treatments (Gliclazide, Vildagliptin, Empagliflozin) and anti-allergy antihistamines (Ebastine, Bilastine), alongside cardiovascular, CNS, and over-the-counter wellness formulations.
Q2: What were Bal Pharma’s consolidated revenue and net profit in FY 2025-26?
In FY 2025-26, Bal Pharma reported consolidated Revenue from Operations of ₹311.66 Crores (Total Income of ₹313.59 Crores) and a consolidated Profit After Tax (PAT) of ₹6.32 Crores, with Basic Earnings Per Share standing at ₹3.95.
Q3: Who are the key promoters and Managing Director of Bal Pharma?
The enterprise is promoted by Mr. Shailesh Siroya, who serves as the Chairman and Managing Director. The promoter and promoter group hold 50.86% of the company’s equity capital, with institutional pharmaceutical conglomerate Micro Labs Limited holding a strategic 12.64% stake.
Q4: Where are Bal Pharma’s manufacturing plants located and what is its export share?
Bal Pharma operates six manufacturing units located in Bangalore (Bommasandra – Units 1 & 2), Rudrapur (Pantnagar, Uttarakhand – Unit 4), Sangli (Maharashtra – Unit 5), Udaipur (Rajasthan – Unit 6), and Kenjal-Pune (Unit 3, currently non-operational). International exports account for approximately 63% of the company’s total revenue, shipping to over 30 countries.
Q5: What is Bal Pharma’s debt profile, credit rating, and net worth?
As of March 31, 2026, Bal Pharma had total consolidated borrowings of ₹159.52 Crores (comprising ₹31.88 Crores of non-current term debt and ₹127.63 Crores of current borrowings and maturities). Its consolidated Net Worth (Total Equity) stood at ₹82.25 Crores, and its credit facilities are rated BBB- / Stable (Long Term) and A3 (Short Term) by Acuité Ratings & Research.
Note: Financial ratios, margins, YoY growth percentages, and % revenue shares are calculated by IndianCompanies.in based on disclosed Ind AS financial statements.
Official Site: https://www.balpharma.com